Latest updates and announcements from Praxis Bioresearch
The FDA has cleared Praxis Bioresearch's Investigational New Drug (IND) application for PRX-P4-003, allowing clinical trials to proceed for the treatment of apathy in Alzheimer's Disease.
Read MorePraxis Bioresearch announced the appointment of Adam Levy to its Board of Directors, bringing extensive experience in biopharmaceutical financial operations and business development.
Read MorePraxis Bioresearch presented promising Phase 0 clinical data for its lead candidate PRX-P4-003 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference.
Read MoreThe National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded Praxis Bioresearch a $2.9 million Fast-Track Small Business Innovation Research (SBIR) grant to support the development of PRX-P4-003 for the treatment of apathy in Alzheimer's Disease.
Read MorePraxis Bioresearch announced positive results from a clinical microdose study demonstrating successful oral activation of its novel prodrug stimulant PRX-P4-003 in humans.
Read MorePraxis Bioresearch announced the issuance of a U.S. patent covering its novel prodrug stimulant PRX-P4-003, strengthening the company's intellectual property portfolio.
Read MoreThe National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) has awarded Praxis Bioresearch a $1.5 million Fast-Track Small Business Innovation Research (SBIR) grant to support the development of PRX-P4-003.
Read MorePraxis Bioresearch announced the publication of positive preclinical data for its novel prodrug stimulant with abuse-deterrent properties in a peer-reviewed scientific journal.
Read MorePraxis Bioresearch presented positive preclinical data for its novel prodrug stimulant with abuse-deterrent properties at the American College of Neuropsychopharmacology (ACNP) Annual Meeting.
Read More